Drug intelligence / Profile preview

F105

Development stage: Phase 1
Lead developer: National Institute of Allergy and Infectious Diseases
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

F105 is a human monoclonal antibody developed for the treatment of HIV infections. It targets the CD4 binding region of the HIV-1 envelope glycoprotein gp120, and has demonstrated the ability to neutralize various HIV strains, including IIIB, SF2, and MN, at concentrations achievable in humans. Clinical trials have investigated its safety, pharmacokinetics, and effects on virologic, immunologic, and serologic parameters in HIV-infected patients.

Other names: F105 human monoclonal antibodyF-105 human monoclonal antibodyF 105 human monoclonal antibody

Targets

Env (HIV-1 envelope glycoprotein)

Beyond the preview

Go deeper on F105.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on F105.

Explore the full profile